Timing treatment for smoldering myeloma: is earlier better?

References

• Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302:1347–1349.
   PubMed Web of Science ®Google Scholar
• Alexanian R. Localized and indolent myeloma. Blood. 1980;56:521–525.
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757.
   PubMed Web of Science ®Google Scholar
• Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Bladé J, Lahuerta -J-J, et al. Management of smoldering myeloma: recommendations of the Spanish Myeloma Group. Med Clin (Barc). 2017;148:517–523.
   PubMed Web of Science ®Google Scholar
• Kyle RA. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Eur J Haematol Suppl. 1989;51:70–75.
   PubMedGoogle Scholar
• Landgren O, Rajkumar SV. Development of early treatment strategies for high-risk myeloma precursor disease in the future. Semin Hematol. 2011;48:66–72.
   PubMed Web of Science ®Google Scholar
• Mateos M-V. When to initiate treatment in smoldering multiple myeloma. Clin Adv Hematol Oncol. 2017;15:751–753.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Landgren O, Mateos M-V. Smoldering multiple myeloma. Blood. 2015;125:3069–3075.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548.
   PubMed Web of Science ®Google Scholar
• Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27:941–946.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Moulopoulos LA, Terpos E, et al. The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia. 2014;28:2402–2403.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582–2590.
   PubMed Web of Science ®Google Scholar
• Pérez-Persona E, Vidriales M-B, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586–2592.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, González-Calle V. Timing of treatment of smoldering myeloma: early treatment. Blood Adv. 2018;2:3045–3049.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Kumar SK, Magen H, et al. Diagnosis and management of smoldering multiple myeloma: the razor’s edge between clonality and cancer. Leuk Lymphoma. 2018;59:288–299.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med. 2011;365:474–475.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Terpos E, Moulopoulos L, et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia. 2013;27:947–953.
   PubMed Web of Science ®Google Scholar
• Sørrig R, Klausen TW, Salomo M, et al. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. Eur J Haematol. 2016;97:303–309.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785–789.
   PubMed Web of Science ®Google Scholar
• Wu V, Moshier E, Leng S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2018;2:1470–1479.
   PubMed Web of Science ®Google Scholar
• Magnano L, Fernández de Larrea C, Elena M, et al. Prognostic impact of serum heavy/light chain pairs in patients with monoclonal gammopathy of undetermined significance and smoldering myeloma: long-term results from a single institution. Clin Lymphoma Myeloma Leuk. 2016;16:e71–e77.
   PubMed Web of Science ®Google Scholar
• Lopez-Anglada L, Cueto-Felgueroso C, Rosiñol L, et al. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. PLoS ONE. 2018;13:e0203392.
   PubMed Web of Science ®Google Scholar
• González-Calle V, Dávila J, Escalante F, et al. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. Leukemia. 2016;30:2026–2031.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27:680–685.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Rajkumar SV, Dispenzieri A, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2017;31:130–135.
   PubMed Web of Science ®Google Scholar
• Aljama MA, Sidiqi MH, Lakshman A, et al. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv. 2018;2:3149–3154.
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Cibeira MT, Montoto S, et al. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc. 2007;82:428–434.
   PubMed Web of Science ®Google Scholar
• Fernández de Larrea C, Isola I, Pereira A, et al. The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor. Leukemia. 2018;32:2082–2094.
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Bladé J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003;123:631–636.
   PubMed Web of Science ®Google Scholar
• Fernández de Larrea C, Isola I, Pereira A, et al. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia. 2018;32:1427–1434.
   PubMed Web of Science ®Google Scholar
• Ravi P, Kumar S, Larsen JT, et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 2016;6:e454.
   PubMed Web of Science ®Google Scholar
• Pérez-Persona E, Mateo G, García-Sanz R, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol. 2010;148:110–114.
   PubMed Web of Science ®Google Scholar
• Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625–1634.
   PubMed Web of Science ®Google Scholar
• Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013;31:4325–4332.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27:1738–1744.
   PubMed Web of Science ®Google Scholar
• Khan R, Dhodapkar M, Rosenthal A, et al. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica. 2015;100:1214–1221.
   PubMed Web of Science ®Google Scholar
• Bolli N, Maura F, Minvielle S, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018;9:3363.
   PubMed Web of Science ®Google Scholar
• Wennmann M, Kintzelé L, Piraud M, et al. Volumetry based biomarker speed of growth: quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget. 2018;9:25254–25264.
   PubMedGoogle Scholar
• Moulopoulos LA, Koutoulidis V, Hillengass J, et al. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer J. 2018;8:95.
   PubMed Web of Science ®Google Scholar
• Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: How? When? Blood. 2019;133:644–651.
   PubMed Web of Science ®Google Scholar
• Siontis B, Kumar S, Dispenzieri A, et al. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J. 2015;5:e364.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014;123:78–85.
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Mick R, Garfall AL, et al. Classifying ultra-high risk smoldering myeloma. Leukemia. 2015;29:751–753.
   PubMed Web of Science ®Google Scholar
• Kumar SK. Timing of treatment of smoldering myeloma: delay until progression. Blood Adv. 2018;2:3050–3053.
   PubMed Web of Science ®Google Scholar
• Hjorth M, Hellquist L, Holmberg E, et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I–a randomized study. Eur J Haematol. 1993;50:95–102.
   PubMed Web of Science ®Google Scholar
• Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Br J Cancer. 2000;82:1254–1260.
   PubMed Web of Science ®Google Scholar
• Barlogie B, van Rhee F, Shaughnessy JD, et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood. 2008;112:3122–3125.
   PubMed Web of Science ®Google Scholar
• Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113:1588–1595.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Laumann KM, Lacy MQ, et al. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 2013;27:220–225.
   PubMed Web of Science ®Google Scholar
• Brighton T, Harrison SJ, Ghez D, et al. A phase 2, randomized, double-blind, placebo-controlled, multicenter study of siltuximab (Anti IL-6 monoclonal antibody) in patients with high-risk smoldering multiple myeloma. Blood. 2017;130:3155.
   Web of Science ®Google Scholar
• Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369:438–447.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1127–1136.
   PubMed Web of Science ®Google Scholar
• Lonial S, Jacobus S, Weiss M, et al. Phase II trial of initial safety and toxicity prior to the phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma (E3A06): a trial coordinated by the eastern cooperative oncology group. Blood. 2012;120:4079.
   Web of Science ®Google Scholar
• Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1:746–754.
   PubMed Web of Science ®Google Scholar
• Ghobrial I. Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. ASH. 2018. [cited 2018 Dec 29]. Available from: https://ash.confex.com/ash/2018/webprogram/Paper117914.html.
   Google Scholar
• Jagannath S, Laubach J, Wong E, et al. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol. 2018;182:495–503.
   PubMed Web of Science ®Google Scholar
• Landgren O Updated results from the phase 2 centaurus study of daratumumab (DARA) monotherapy in patients with intermediate-risk or high-risk Smoldering Multiple Myeloma (SMM). ASH. 2018 [cited 2019 Jan 2]. Available from: https://ash.confex.com/ash/2018/webprogram/Paper113467.html.
   Google Scholar
• Bustoros MPhase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. ASH. 2018 [cited 2019 Jan 2]. Available from: https://ash.confex.com/ash/2018/webprogram/Paper117871.html.
   Google Scholar
• MD BGD. ASCENT Trial to Treat High-Risk Smoldering Multiple Myeloma Launching Across the US [Internet]. Multiple Myeloma: International Myeloma Foundation. 2018 [cited 2019 Jan 2]. Available from: https://www.myeloma.org/blog/dr-duries/ascent-trial-treat-high-risk-smoldering-multiple-myeloma-launching-across-us.
   Google Scholar
• Mateos M-V. Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. ASH; 2018 [cited 2019 Jan 2]. Available from: https://ash.confex.com/ash/2018/webprogram/Paper112656.html.
   Google Scholar
• González-Calle V, Mateos MV. Monoclonal gammopathies of unknown significance and smoldering myeloma: assessment and management of the elderly patients. Eur J Intern Med. 2018;58:57–63.
   PubMed Web of Science ®Google Scholar
• Landgren O. Shall we treat smoldering multiple myeloma in the near future? Hematology Am Soc Hematol Educ Program. 2017;2017:194–204.
   PubMedGoogle Scholar